surf1944
13 years ago
Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency
Business WirePress Release: Allos Therapeutics, Inc. – Mon, Jan 30, 2012 8:30 AM EST
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ: ALTH - News) today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA’s Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN® (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy. PTCL comprises a biologically diverse group of aggressive, rare blood cancers that have a worse prognosis than most other types of lymphoma, including B-cell lymphoma. According to current CHMP guidelines, a final opinion on the re-examination could be issued by the EMA within four to five months.
“We believe FOLOTYN has the potential to offer an important new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma, an indication for which there are currently no EMA-approved therapies and no accepted standard of care,” said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. “We look forward to working closely with our partner Mundipharma and the CHMP during the re-examination process.”
Pralatrexate has orphan medicinal product designation in Europe for the treatment of PTCL (nodal, other extranodal, and leukaemic/disseminated). In the E.U., orphan medicinal product designation is conferred upon investigational products for diseases that affect fewer than five in 10,000 patients. Products with orphan designation that are the first to be approved for a specific indication, and continue to meet the requirements for orphan designation, receive up to ten years of market exclusivity in the E.U.
surf1944
13 years ago
7:22AM Allos Therapeutics beats by $0.05, beats on revs (ALTH) 1.47 : Reports Q3 (Sep) loss of $0.11 per share, $0.05 better than the Capital IQ Consensus Estimate of ($0.16); revenues rose 73.2% year/year to $14.2 mln vs the $12.37 mln consensus. Co is lowering prior operating expense guidance for full year 2011. Prior operating expense guidance for the full year 2011 was $95 to $98 million. Allos now expects total operating costs and expenses, excluding cost of sales, cost of license and other revenue and non-cash stock-based compensation expense, to approximate $82 to $84 mln
mlkrborn
13 years ago
ALTH $1.41.. Termination news ; halted briefly.
9:27AM Allos Therapeutics confirms termination of merger agreement with AMAG Pharmaceuticals (ALTH) 1.46 : ALTH confirms that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub on July 19, 2011, as amended on August 8, 2011, has been terminated. The Merger Agreement was terminated following the October 21, 2011, special meeting of AMAG stockholders at which AMAG's stockholders voted against the issuance of shares of AMAG common stock to Allos' stockholders in the proposed merger. Separately, a majority of Allos' stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Allos stockholders also held on October 21, 2011. (Stock is halted) See our 9:11 comment for more color.
9:11AM AMAG Pharma announced results from today's meeting, at which a proposal to approve the issuance of shares of AMAG common stock to the stockholders of Allos Therapeutics (ALTH) in connection with the merger with Allos did not receive the necessary votes to be adopted (AMAG) 13.64 : In accordance with the terms of the merger agreement with Allos, AMAG will terminate the merger agreement and pay Allos $2 million to cover expenses Allos has incurred related to the proposed transaction. "AMAG's Board and management team have had a constructive dialogue with our stockholders over the past three months and we value their perspectives...While our strategy of adding products to our portfolio to leverage our infrastructure is important to our long-term success, we are committed to pursuing all opportunities to enhance stockholder value."
mlkrborn
13 years ago
This is why!Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos
By Adam Feuerstein 10/10/11 - 10:46 AM EDT
Allos Therapeutics Inc.| ALTH
DOWN
LEXINGTON, Mass. (TheStreet) --Hedge fund manager Martin Shkreli has taken a 5.8% ownership stake in Amag Pharmaceuticals(AMAG_), an escalation of his effort to wrest control of the struggling drug maker and stop a planned merger with Allos Therapeutics(ALTH_).
Shkreli must still demonstrate that he has the funds necessary to make good on his previously announced $18-a-share offer for Amag. But Shkreli's purchase of 1.25 million Amag shares -- disclosed for the first time in a regulatory filing Friday night -- may persuade on-the-fence shareholders to accept his proposals and reject Amag's plans to merge with Allos.
Amag is fighting a two-front war at the moment. First, it must secure the support of a majority of its shareholders at an Oct. 21 vote to complete the Allos merger. Second, Amag is being force to fend off Shkreli's activism, including a proposal seeking shareholder approval to remove six of the seven directors on Amag's board and replace them with five MSMB nominees who would put a stop to the Allos merger.
Adage Capital Management and Palo Alto Investors, owners of 17.5% and 15% of Amag, respectively, are still said to be opposing the Allos merger because of concerns about the financial and strategic rationale behind the deal, according to sources familiar with the situation.
Amag will have a very difficult time completing the Allos merger without the support of Adage and Palo Alto. Whether the two largest Amag shareholders also support Shkreli's efforts to shake up Amag's board is not clear, but killing off the Allos merger will almost certainly provoke significant changes at Amag.
"Voting no on the Allos deal is a referendum against Amag's management team," said an Amag shareholder who asked not be identified but is voting to stop the Allos merger.
If the current Amag board survives, directors will face tremendous pressure to fire Amag CEO Brian Pereira and put the company up for sale. For all intent and purpose, a sale of Amag will really be a simple auction of the company's only asset Feraheme, an injectable iron replacement therapy for anemia in patients with chronic kidney disease.
mlkrborn
13 years ago
ALTH $1.43 on merger update news:
Allos Therapeutics Continues to Work Toward Completion of Merger with AMAG Pharmaceuticals
businesswire
Related Quotes
Symbol Price Change
ALTH 1.40 -0.35
Press Release Source: Allos Therapeutics, Inc. On Monday October 10, 2011, 8:00 am EDT
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (Nasdaq:ALTH - News) today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos’ definitive proxy statement filed with the SEC on September 15, 2011. On October 7, 2011, the publicly traded pharmaceutical company that had previously submitted a proposal to acquire Allos for $2.20 per share in cash and stock delivered a letter to Allos withdrawing its revised proposal to acquire Allos. As a result, Allos is no longer providing information to, or engaging in discussions or negotiations with, that company with respect to the revised acquisition proposal or any other acquisition proposal.
mlkrborn
13 years ago
AMAG shareholder is so pissed of AMAG's acqusition of ALTH, it wants AMAG to scrap the deal and buy AMAG.
Amag Pharma receives unsolicited acquisition offer
Amag Pharma receives $381 million unsolicited acquisition offer from MSMB Capital Management
ap
Companies:
o Allos Therapeutics, Inc.
o AMAG Pharmaceuticals, Inc.
Related Quotes
Symbol Price Change
ALTH 1.75 -0.03
Chart for Allos Therapeutics, Inc.
AMAG 15.90 +1.51
Tom Murphy, AP Business Writer, On Wednesday August 3, 2011, 11:32 am
INDIANAPOLIS (AP) -- Amag Pharmaceuticals Inc. shareholder MSMB Capital Management is so disappointed by the drugmaker's recently announced plan to buy Allos Therapeutics that it wants to scrap that deal and buy Amag outright.
The hedge fund said Wednesday it has offered to buy shares of Lexington, Mass.-based Amag it doesn't already own for $18 each in cash. The offer, worth about $378 million, represents a 25 percent premium over the stock's closing price Tuesday of $14.39. MSMB Chief Investment Officer Martin Shkreli told The Associated Press his firm owns less than 5 percent of Amag and had recently increased its stake. He declined to be more specific.
Shares of Amag jumped nearly 9 percent, or $1.25, to $15.64 in late Wednesday morning trading. Allos Therapeutics shares fell 4 cents, or more than 2 percent, to $1.74.
Amag makes Feraheme for the treatment of iron deficiency anemia in adults with chronic kidney disease. Last month, it announced a plan to buy drugmaker Allos Therapeutics Inc. of Westminster, Colo., for about $268 million in stock in a deal designed to bolster its commercial portfolio and cuts costs.
That proposal left Shkreli surprised and disappointed, according to an Aug. 2 letter he sent to Amag's board of directors. Shkreli told the board he felt they overpaid for Allos, and he didn't like the stock-for-stock combination.
"It's not a healthy transaction," he said in a brief phone interview. "If you've been a shareholder for a long time, and you're waiting for a premium price, you didn't get it with this transaction."
Amag said in a brief statement it would carefully consider the unsolicited MSMB offer, but a company spokesman declined additional comment.
Amag's share price has tumbled about 24 percent since closing at $19.07 July 19, the day before it announced the Allos deal. Shkreli noted that the company's stock has not responded well, and the MSMB offer gives shareholders an alternative to the "poorly viewed" Allos transaction.
Under terms of that deal, Allos stockholders will get 0.1282 shares of Amag stock for each share of Allos. Amag shareholders will own about 61 percent of the combined company, while Allos stockholders will have 39 percent.
Amag will nominate five of the nine members of the new company's board, and its CEO, Dr. Brian J.G. Pereira, will serve as CEO of the new company. Michael Narachi will remain chairman. The combined company will be based in Lexington.
Shkreli said MSMB is prepared to raise its price if that is warranted and if it receives the time and access it needs to conduct due diligence on Amag. MSMB requested that Amag respond by Aug. 15 and said its offer is contingent on an agreement being reached before Sept. 1. It added that its offer is not subject to any financing condition.
"It is imperative that the company be sold now, the transaction with Allos terminated and further erosion of stockholder value be prevented," Shkreli wrote.
Penny Roger$
13 years ago
I think I saw something about a law suit.. hmmm Law Office of Brodsky & Smith, LLC Announces Investigation of Allos Therapeutics, Inc. http://finance.yahoo.com/news/Law-Office-of-Brodsky-Smith-bw-492395162.html?x=0
starting to understand why these news releases come out when they do. Interesting stuff. reverse promotions.
Share Statistics
Avg Vol (3 month)3: 1,230,870
Avg Vol (10 day)3: 535,900
Shares Outstanding5: 105.61M
Float: 68.47M
% Held by Insiders1: 1.55%
% Held by Institutions1: 97.80%
Shares Short (as of Jun 30, 2011)3: 6.39M
Short Ratio (as of Jun 30, 2011)3: 4.50
Short % of Float (as of Jun 30, 2011)3: 8.10%
Shares Short (prior month)3: 7.07M
mlkrborn
13 years ago
ALTH and AMAG merge with stox exchange arrangement: ALTH $2.00 vs AMAG $16.00 stox now!
BOSTON (MarketWatch) -- Shares of AMAG Pharmaceuticals /quotes/zigman/107237/quotes/nls/amag AMAG -13.95% dropped 14% to $16.46 on Wednesday following news that it plans to merge with Allos Therapeutics /quotes/zigman/81880/quotes/nls/alth ALTH -1.94% in an all-stock deal valued at around $686 million. Following the merger, AMAG shareholders will hold a 61% stake in the new company, while Allos stockholders will have 39%. The combined company will be headquartered in Lexington, Mass., and will be renamed "to reflect its strategic focus," the companies said. The deal is expected to close in the fourth quarter. Shares of Allos were down 1%.
surf1944
13 years ago
Amag-Allos: Worst Bio-Merger in History
By Adam Feuerstein 07/20/11 - 07:56 AM EDT
LEXINGTON, Mass. (TheStreet) -- Amag Pharmaceuticals(AMAG_) is merging with Allos Therapeutics(ALTH_) in what might be the nuttiest, most nonsensical business combination in biotech history.
More from Adam Feuerstein
Alkermes Offers Post-Merger Vision
5 Biotech Drug-Launch Stocks to Watch
bio tech takeunder
The only thing Amag and Allos have in common is that they've largely failed initial efforts to sell their respective drugs, neither of which have anything to do with each other.
Amag's commercial launch of Feraheme, an injectable iron replacement therapy for anemia in patients with chronic kidney disease, has been a major disappointment. The same can be said for Allos' lymphoma cancer drug Folotyn.
Ideally, mergers bring together two companies that can capitalize on their respective strengths to make the sum better, stronger, more capable than the individual parts. Wednesday's merger of Amag and Allos does no such thing. It's just two disparate and under-performing biotech companies getting hitched to, at best, save some money.
"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported by a more efficient organizational structure," said Brian Pereira, CEO of Amag in a statement that fails on so many levels to rationalize this deal.
Pereira, by the way, will retain the CEO title in the as-yet-unnamed combined company.
Under terms of the deal, Allos shareholders will receive a fixed ratio of 0.128 shares of Amag common stock for each share of Allos common stock they own. At Amag's Tuesday closing price of $19.07, the deal is valued at approximately $260 million.
Allos received U.S. approval for Folotyn in September 2009. At that time, Allos shares traded for around $8 a share. That was basically the high point for Allos's stock price, which closed Tuesday at $2.06 a share.
Amag's Feraheme was approved in the U.S. in July 2009 when Amag shares traded around $56 a share. Like Allos, Amag' stock price never saw brighter days. The stock fell steadily as Feraheme sales lagged expectations.
The merger of Amag and Allos: Not exactly a match made in heaven.
--Written by Adam Feuerstein in Boston.
surf1944
13 years ago
1:46AM Allos Therapeutics reports data shows activity of FOLOTYN in patients with relapsed or refractory peripheral T-Cell lymphoma following treatment with CHOP (ALTH) 2.01 : CO announces results from a retrospective analysis of data from the co's pivotal PROPEL trial, which assessed the safety and efficacy of single-agent FOLOTYN as a second-line treatment in patients with relapsed or refractory peripheral T-cell lymphoma who received CHOP as their first-line treatment. The highlights of the study include: Objective responses with FOLOTYN were observed in seven patients (47%) as assessed by independent central review and in six patients (40%) as assessed by local investigators. Complete responses, meaning there was a complete regression of all signs of disease in response to treatment with FOLOTYN, were observed in three of the 15 patients (20%), based on independent central review, and four of the 15 patients (27%), based on local investigator review. Two of these patients went on to receive a stem cell transplant after responding to FOLOTYN and sustained complete responses for 20.9 and 27.2 months through the time of last contact. Median duration of response, by independent central review, had not yet been reached at the time of analysis; by local investigator review, the median duration of response was 12.5 months. Progression-free survival was 8.1 months by independent central review and 7.4 months per local investigator review. Median overall survival was not able to be estimated as 11 (75%) of the 15 patients were still alive at the time of last contact; the 12-month overall survival estimate was 73%.
surf1944
13 years ago
2:53AM Allos Therapeutics presents data suggesting treatment with FOLOTYN reverses trend of progressive resistance observed in patients with drug-resistant relapsed or refractory peripheral T-Cell Lymphoma (ALTH) 2.01 : Co reports results from a retrospective analysis of data from the co's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. In patients who received three or more lines of therapy prior to enrolling in PROPEL, response rates decreased from 56% to 30%; median progression-free survival decreased from 213.5 days to 95 days. In patients who received two or more lines of therapy prior to enrolling in PROPEL, response rates decreased from 38% to 29%; median progression-free survival decreased from 144 days to 89.5 days. Following treatment with FOLOTYN, response rates and progression-free survival increased relative to the previous line of therapy: In patients who received three or more prior therapies, response rates increased from 30% to 40%; median progression-free survival increased from 95 days to 134 days. In patients who received two or more prior therapies, response rates increased from 29% to 40%; median progression-free survival increased from 89.5 days to 119 days.
mlkrborn
13 years ago
ALTH up from its 52 weeks low level of $1.85 to $2.10 with researach presentation announcement:
COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma
Date : 06/16/2011 @ 2:30AM
Source : Business Wire
Stock : Allos Therapeutics, Inc. (ALTH)
Quote : 2.1 0.25 (13.51%) @ 7:26AM
COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Intraday Stock Chart
Today : Thursday 16 June 2011
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma (PTCL). The registry, supported by Allos Therapeutics, Inc., is guided by a prestigious multi-disciplinary steering committee. Data were presented in a poster presentation at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 15-18) by Dr. Francine Foss.
PTCL is a biologically diverse group of aggressive, mature T and NK (natural killer) cell non-Hodgkin lymphomas with similar outcomes, which include PTCL-NOS (PTCL not otherwise specified), AITL (angioimmunoblastic T-cell lymphoma), and ALCL (anaplastic large-cell lymphoma).1 The prognosis for patients with PTCL is generally poor for most subtypes.2
“These data from COMPLETE represent a first step toward increasing the understanding of peripheral T-cell
surf1944
13 years ago
3:09AM Allos Therapeutics: COMPLETE registry provides first glance into treatment patterns for patients with peripheral T-Cell lymphoma (ALTH) 1.85 : Co presents initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma. Baseline characteristics presented show the average patient age to be 58 years with slightly more men enrolled in the registry to date (44 men (59%) and 30 female (41%); the most common PTCL subtypes are PTCL-NOS (18 of 74 patients; 24%), ALCL (13 of 74 patients; 18%), AITL (11 of 74 patients; 15%), T/NK cell lymphoma, nasal type (7 of 74 patients; 10%), and transformed mycosis fungoides (7 of 74 patients; 10%). Treatment records show the most common initial treatment to be induction chemotherapy alone (17 of 26 patients; 65%).
mlkrborn
14 years ago
4:06PM Allos Therapeutics and Mundipharma announce strategic collaboration for Folotyn (ALTH) 2.84 -0.04 : Co and Mundipharma International Corporation Limited jointly announce that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN. Under the agreement, Allos retains full commercialization rights for FOLOTYN in the United States and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries. Under the collaboration, Allos will receive an upfront payment of $50 million and potential regulatory and commercial progress- and sales-dependent milestone payments of up to $310.5 million. Allos is also entitled to receive tiered double-digit royalties based on net sales of FOLOTYN within Mundipharma's licensed territories. Allos and Mundipharma will jointly fund development costs, initially on a 60:40 basis, which will change to a 50:50 basis if certain pre-defined milestones are achieved, including approval of the MAA currently under review to market FOLOTYN in the European Union.
surf1944
14 years ago
Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011
Press Release Source: Allos Therapeutics, Inc. On Thursday February 17, 2011, 9:00 am EST
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc. (NASDAQ:ALTH - News), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2010 on Thursday, March 3, 2011, after the financial markets close. Following the release of the financial results, Allos management will provide a corporate update and review of the fourth quarter and full year 2010 results via audio webcast conference call on Thursday, March 3, 2011, at 4:30 p.m. Eastern Time (ET).
To access the live audio webcast or the subsequent archived recording, visit the “Investors - Presentations and Events” section of the Company’s website at www.allos.com. Alternatively, callers may participate in the conference call by dialing 1-800-762-8779 (U.S.) or +480-629-9771 (Canada and international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through March 17, 2011. To access the replay, callers should dial 1-800-406-7325 (domestic) or +1-303-590-3030 (international) and use passcode 4410612#.
surf1944
14 years ago
Bought some ALTH for a trade, the company has plenty of cash & I like the short info. Hopeful for a short covering reversal in the coming days....
Avg Vol (3 month)3: 1,236,530
Avg Vol (10 day)3: 1,432,100
Shares Outstanding5: 105.34M
Float: 60.17M
% Held by Insiders6: 0.49%
% Held by Institutions6: 78.70%
Shares Short (as of Dec 31, 2010)3: 10.26M
Short Ratio (as of Dec 31, 2010)3: 8.70
Short % of Float (as of Dec 31, 2010)3: 13.10%
Shares Short (prior month)3: 10.95M
surf1944
14 years ago
Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress
Allos Therapeutics (MM) (NASDAQ:ALTH)
Today : Friday 10 September 2010
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that results from the Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress — Milan, Italy from October 8-12, 2010.
"This is the first time that Allos will have an opportunity to present the results from the Phase 2b trial of FOLOTYN in patients with advanced non-small cell lung cancer,” said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. “We believe these are important results for the cancer community – generating data on the efficacy and safety profile for FOLOTYN in this treatment setting where there remains a high unmet need – and are pleased that the ESMO Congress has accepted these data as a late-breaking abstract to be highlighted in an oral presentation.”
The randomized, open-label, international, multi-center Phase 2b study comparing FOLOTYN versus erlotinib, marketed as TARCEVA®, enrolled 201 current or former smokers with Stage IIIB/IV (advanced) NSCLC who had received one or two previous treatments including at least one prior platinum-based chemotherapy regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival. The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival and response rate, both compared to erlotinib, and the safety and tolerability of FOLOTYN.
Presentation details are as follows:
Presentation Date/Time: Monday, October 11, 13:15 – 14:30 CEST
Poster Title: “Randomized Phase 2b Study of Pralatrexate vs Erlotinib in Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) after Failure of Prior Platinum-Based Therapy”
First Author: K. Kelly, University of Kansas, Kansas City/US
Abstract Number: LBA17
surf1944
14 years ago
25-Aug-2010
Change in Directors or Principal Officers, Regulation FD Disclosure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) James V. Caruso, Executive Vice President and Chief Commercial Officer, departed Allos Therapeutics, Inc. ("Allos") effective Tuesday, August 24, 2010.
Item 7.01 Regulation FD Disclosure.
Effective Tuesday, August 24, 2010, Allos promoted Michael Schick to Vice President, Sales and Marketing, reporting to Paul Berns, President and Chief Executive Officer. In his new expanded role, Mr. Schick will be responsible for leading Allos' sales and marketing activities for FOLOTYN? (pralatrexate injection).
Mr. Schick has served as Vice President of Marketing of Allos since August 2009. Prior to joining Allos, Mr. Schick served as Associate Vice President, Oncology Marketing at ImClone Systems from October 2007 to July 2009, where he was responsible for the Erbitux? (cetuximab injection) franchise across multiple indications. From February 2006 to October 2007, Mr. Schick was Executive Director, Oncology Global Marketing at Amgen Inc., where he was responsible for marketing Neulasta? (pegfilgrastim) and Aranesp (darbepoetin alfa injection). From November 2004 to January 2006, Mr. Schick served as Director, Marketing, Oncology at Pharmacyclics, Inc. Prior to that, Mr. Schick served in a variety of commercial roles at Bristol Myers Squibb, including sales, strategic planning and product management focused on multiple brands including Taxol? (paclitaxel injection) and Paraplatin? (carboplatin for injection). Mr. Schick earned a Bachelor of Arts degree from Villanova University.
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Ask ADVFN Intelligence (AI)
hedge_fun
13 years ago
QualityStocks
14 years ago
